Fluorodeoxyglucose Positron Emission Tomography as Predictive Factor for the Outcome of Head and Neck Cancer Patients | ||||
| Egyptian Journal Nuclear Medicine | ||||
| Article 3, Volume 3, Issue 3, December 2010, Page 18-26 | ||||
| Document Type: Original Paper, Oncology | ||||
| DOI: 10.21608/egyjnm.2010.5497 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| Ashraf Farrag* | ||||
| Clinical Oncology departement, Assiut University Hospital, Assiut, Egypt | ||||
| Abstract | ||||
| Objectives: The aim of this study was to determine if fluorodeoxyglucose positron emission tomography (FDG-PET) uptake can be used in pretreatment assessment as an additional prognostic factor for outcome in head and neck cancer patients receiving radiotherapy by helical tomotherapy (Hi-Art Tomotherapy®) +/- chemotherapy. Methods: Between June 2005 and March 2008, 58 patients with a biopsy proven head and neck cancer (HNC) were treated at the Universitair Ziekenhuis Brussel (UZ Brussel). All patients underwent a baseline FDG-PET before treatment. The maximum Standardized Uptake Value (SUVmax) was measured within the lesions. Median SUVmax was used as a cutoff to categorize patients into high and low SUVmax groups. Results: Median SUVmax = 7.92. Median SUVmax for patients who died was significantly higher than living patients (9.16 vs. 7.32, respectively, p= 0.037). 3-years Overall survival (OS) was 80% vs. 54% (p = 0.009) and disease free survival (DFS) was 83% vs. 41% (p = 0.018) for low and high SUVmax groups, respectively. Multivariate analysis also confirmed these observations. Conclusion: PET-FDG scan before treatment is a good predictor of outcome in HNC patients. It may helps in early identification of patients with poor prognosis for perhaps other therapeutic approaches. | ||||
| Keywords | ||||
| FDG-PET; SUV; Helical tomotherapy; head and neck cancer; predictive factor | ||||
|
Statistics Article View: 169 |
||||
